Belatacept

Summary

Belatacept (CHEMBL1742990) is an approved protein (ATC L04AA28) targeting CD80 and CD86; indicated across 9 conditions including immune system disorder and graft versus host disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L04AA28
• Targets: 2 (CD80, CD86)
• Indications: 9 conditions
• Clinical trials: 64

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742990
Name	Belatacept
Type	Protein
Max phase	4
ATC	L04AA28

Also known as: Belatacept, BMS-224818, LEA29Y, Nulojix, Nujolix, BELATACEPT

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CD80	CD80	Inhibition		0.2%	P33681
CD86	CD86	Inhibition		0.4%	P42081

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): CD80, CD86.

Top Reactome pathways

19 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	2	CD80, CD86
Cytokine Signaling in Immune system	2	CD80, CD86
Adaptive Immune System	2	CD80, CD86
Signal Transduction	2	CD80, CD86
Disease	2	CD80, CD86
Immune System	2	CD80, CD86
Negative regulation of the PI3K/AKT network	2	CD80, CD86
PI3K/AKT Signaling in Cancer	2	CD80, CD86
Constitutive Signaling by Aberrant PI3K in Cancer	2	CD80, CD86
Regulation of T cell activation by CD28 family	2	CD80, CD86
Co-stimulation by CD28	2	CD80, CD86
CD28 dependent PI3K/Akt signaling	2	CD80, CD86
CD28 dependent Vav1 pathway	2	CD80, CD86
Co-inhibition by CTLA4	2	CD80, CD86
Signaling by Interleukins	2	CD80, CD86
Diseases of signal transduction by growth factor receptors and second messengers	2	CD80, CD86
Interleukin-10 signaling	2	CD80, CD86
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	2	CD80, CD86
Intracellular signaling by second messengers	2	CD80, CD86

Dominant GO biological processes

GO term	Targets
immune response	2
cell surface receptor signaling pathway	2
T cell costimulation	2
positive regulation of interleukin-2 production	2
positive regulation of T cell proliferation	2
T cell activation	2
negative regulation of T cell proliferation	2
positive regulation of DNA-templated transcription	2
negative regulation of T cell receptor signaling pathway	2
positive regulation of T cell receptor signaling pathway	2
negative regulation of T cell activation	2
cellular response to lipopolysaccharide	2
immune system process	2
symbiont entry into host cell	2
negative regulation of T cell mediated immunity	1

Indications & clinical

Indications

9 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
immune system disorder	4	MONDO:0005046	EFO:0000540
graft versus host disease	3	MONDO:0013730	EFO:0004599
chronic kidney disease	3	MONDO:0005300	MONDO:0024327
proteinuria	2	MONDO:0003634	HP:0000093
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
rheumatoid arthritis	1	MONDO:0008383	EFO:0000685

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 64.

Phase distribution

Phase	Trials
PHASE2	26
PHASE4	14
Not specified	7
PHASE1/PHASE2	6
PHASE3	5
PHASE1	5
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06291077	PHASE4	NOT_YET_RECRUITING	Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients -
NCT01729494	PHASE4	COMPLETED	Belatacept Early Steroid Withdrawal Trial
NCT01766050	PHASE4	COMPLETED	Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
NCT01875224	PHASE4	UNKNOWN	Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression
NCT01953120	PHASE4	COMPLETED	Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
NCT02078193	PHASE4	COMPLETED	Efficacy of Belatacept in Reducing DSA
NCT02103855	PHASE4	COMPLETED	Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
NCT02130817	PHASE4	WITHDRAWN	Belatacept in Kidney Transplantation of Moderately Sensitized Patients
NCT02152345	PHASE4	COMPLETED	Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
NCT02213068	PHASE4	COMPLETED	Belatacept 3 Month Post Transplant Conversion Study
NCT02560558	PHASE4	COMPLETED	Bela 8 Week Dosing
NCT02939365	PHASE4	WITHDRAWN	Precision Medicine Offers Belatacept Monotherapy
NCT04786067	PHASE4	COMPLETED	Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
NCT04849533	PHASE4	UNKNOWN	Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)
NCT04877288	PHASE3	RECRUITING	A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT05562869	PHASE3	RECRUITING	Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
NCT01820572	PHASE3	COMPLETED	A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
NCT01921218	PHASE3	COMPLETED	Belatacept Therapy for the Failing Renal Allograft
NCT04013620	PHASE3	UNKNOWN	CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction
NCT02310867	PHASE2	RECRUITING	Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
NCT04180085	PHASE2	RECRUITING	Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)
NCT04477629	PHASE2	RECRUITING	Belatacept in De Novo Heart Transplantation
NCT04827979	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Daratumumab and Belatacept for Desensitization
NCT04955366	PHASE2	ACTIVE_NOT_RECRUITING	Abatacept Conversion in Kidney Transplantation
NCT05017545	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Carfilzomib and Belatacept for Desensitization
NCT06055608	PHASE2	RECRUITING	Advancing Transplantation Outcomes in Children
NCT06478017	PHASE2	RECRUITING	Belatacept in Heart Transplantation
NCT00035555	PHASE2	COMPLETED	Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
NCT00276250	PHASE2	COMPLETED	Islet Transplantation Using Abatacept
NCT00279760	PHASE1/PHASE2	COMPLETED	Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
NCT00346151	PHASE2	TERMINATED	Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
NCT00402168	PHASE2	COMPLETED	A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
NCT00455013	PHASE2	COMPLETED	A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
NCT00468403	PHASE2	COMPLETED	LEA29Y (Belatacept) Emory Edmonton Protocol
NCT00501709	PHASE1/PHASE2	COMPLETED	Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus
NCT00565773	PHASE2	COMPLETED	Belatacept Post Depletional Repopulation to Facilitate Tolerance
NCT00578448	PHASE2	COMPLETED	Belatacept Pharmacokinetic Trial in Renal Transplantation
NCT01436305	PHASE2	TERMINATED	Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
NCT01790594	PHASE2	TERMINATED	Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
NCT01791491	PHASE2	COMPLETED	Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).